(Reuters)—Numerous small biotechnology companies have been all but shut out of the capital markets, leaving many with no choice but to consider a sale to larger peers. The Nasdaq Biotech Index is down nearly 30% since September, when Democratic presidential candidate Hillary Clinton criticized drug companies’ “price gouging” on Twitter and sparked concerns about a…
Search results for: drug pricing
Dr. Michael Weinblatt Discusses Current & Future RA Therapies
According to former ACR President Michael Weinblatt, MD, the future of drug therapies for patients with RA rests in the careful and intelligent prescription of current medications and treatment combinations, as well as better patient access through lower costs…
Prepare NOW for ICD-10 Medical Coding Transition
The ICD-10 page on the Centers for Medicare & Medicaid Services (CMS) website features a countdown clock that shows the time left until Oct. 1, 2015, the date on which compliance with the new code set becomes mandatory. By the time this issue goes to press, the clock will read 90 or fewer days. Time…
Can DIY Medicine Tame Rampaging Healthcare Costs?
High health insurance deductibles, physician charges, medication expenses spur patients to seek less costly lab testing, surgical procedures, prescription drugs
Rheuminations: New Rules for Rheumatologists
Transparent hospital costs, salary caps for senior hospital executives, and no more faxes top one rheumatologist’s wish list for revised healthcare rules
No Easy Solution for Lack of Transparency in the Practice of Medicine
Several well-publicized episodes highlight the apparent lack of disclosure of conflicts of interest in medicine, but will disclosure laws fix the problem or add to the confusion?
Rheumatology Professionals and Patient Advocates Take Their Stories to Capitol Hill
This year’s Advocates for Arthritis conference was the American College of Rheumatology’s largest and most successful fly-in to date
American College of Rheumatology Leads Charge to Address Excessive Patient Cost Sharing
The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.
American College of Rheumatology (ACR) Advocates for Improved Access to Critical Treatments
The ACR is promoting federal legislation to eliminate high cost sharing for specialty tier medications in all states.
Global Perspective
Healthcare policy varies by country, but U.S. lags in key areas